These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3139 related articles for article (PubMed ID: 6852975)
1. Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells. Livingston PO; Takeyama H; Pollack MS; Houghton AN; Albino A; Pinsky CM; Oettgen HF; Old LJ Int J Cancer; 1983 May; 31(5):567-75. PubMed ID: 6852975 [TBL] [Abstract][Full Text] [Related]
2. [Vaccine therapy of malignant melanoma. II. Serological evaluation of the immune responses to the injection using allogeneic melanoma cell vaccine]. Takeyama H; Watanabe T; Livingston PO Gan To Kagaku Ryoho; 1983 Jul; 10(7):1624-33. PubMed ID: 6870307 [TBL] [Abstract][Full Text] [Related]
3. Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Livingston PO; Albino AP; Chung TJ; Real FX; Houghton AN; Oettgen HF; Old LJ Cancer; 1985 Feb; 55(4):713-20. PubMed ID: 2981601 [TBL] [Abstract][Full Text] [Related]
4. The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines. Livingston PO; Kaelin K; Pinsky CM; Oettgen HF; Old LJ Cancer; 1985 Nov; 56(9):2194-200. PubMed ID: 4052966 [TBL] [Abstract][Full Text] [Related]
5. Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. Houghton AN; Taormina MC; Ikeda H; Watanabe T; Oettgen HF; Old LJ Proc Natl Acad Sci U S A; 1980 Jul; 77(7):4260-4. PubMed ID: 6933476 [TBL] [Abstract][Full Text] [Related]
6. [Serological analysis of melanoma patients receiving autologous melanoma cell vaccines]. Watanabe T Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt):261-72. PubMed ID: 6881976 [TBL] [Abstract][Full Text] [Related]
8. Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine. Bystryn JC; Henn M; Li J; Shroba S Cancer Res; 1992 Nov; 52(21):5948-53. PubMed ID: 1382848 [TBL] [Abstract][Full Text] [Related]
9. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. Anichini A; Maccalli C; Mortarini R; Salvi S; Mazzocchi A; Squarcina P; Herlyn M; Parmiani G J Exp Med; 1993 Apr; 177(4):989-98. PubMed ID: 8459226 [TBL] [Abstract][Full Text] [Related]
10. Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody. Real FX; Mattes MJ; Houghton AN; Oettgen HF; Lloyd KO; Old LJ J Exp Med; 1984 Oct; 160(4):1219-33. PubMed ID: 6237165 [TBL] [Abstract][Full Text] [Related]
11. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity. de Vries JE; Spits H J Immunol; 1984 Jan; 132(1):510-9. PubMed ID: 6197458 [TBL] [Abstract][Full Text] [Related]
12. Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens. Shiku H; Takahashi T; Oettgen HF J Exp Med; 1976 Oct; 144(4):873-81. PubMed ID: 978138 [TBL] [Abstract][Full Text] [Related]
13. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction. Hom SS; Topalian SL; Simonis T; Mancini M; Rosenberg SA J Immunother (1991); 1991 Jun; 10(3):153-64. PubMed ID: 1868040 [TBL] [Abstract][Full Text] [Related]
14. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. Darrow TL; Slingluff CL; Seigler HF J Immunol; 1989 May; 142(9):3329-35. PubMed ID: 2785141 [TBL] [Abstract][Full Text] [Related]
15. Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients. Walton SM; Gerlinger M; de la Rosa O; Nuber N; Knights A; Gati A; Laumer M; Strauss L; Exner C; Schäfer N; Urosevic M; Dummer R; Tiercy JM; Mackensen A; Jaeger E; Lévy F; Knuth A; Jäger D; Zippelius A J Immunol; 2006 Dec; 177(11):8212-8. PubMed ID: 17114498 [TBL] [Abstract][Full Text] [Related]
16. Preparation and characterization of a polyvalent human melanoma antigen vaccine. Bystryn JC; Jacobsen S; Harris M; Roses D; Speyer J; Levin M J Biol Response Mod; 1986 Jun; 5(3):211-24. PubMed ID: 3723138 [TBL] [Abstract][Full Text] [Related]
17. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Jäeger E; Bernhard H; Romero P; Ringhoffer M; Arand M; Karbach J; Ilsemann C; Hagedorn M; Knuth A Int J Cancer; 1996 Apr; 66(2):162-9. PubMed ID: 8603805 [TBL] [Abstract][Full Text] [Related]
18. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. Real FX; Houghton AN; Albino AP; Cordon-Cardo C; Melamed MR; Oettgen HF; Old LJ Cancer Res; 1985 Sep; 45(9):4401-11. PubMed ID: 4028024 [TBL] [Abstract][Full Text] [Related]
19. A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine. Hayashi Y; Hoon DS; Foshag LJ; Park MS; Terasaki PI; Morton DL Cancer; 1993 Aug; 72(3):750-9. PubMed ID: 8334627 [TBL] [Abstract][Full Text] [Related]
20. Isolation and immunochemical characterization of antibodies from the sera of cancer patients which are reactive against human melanoma cell membranes by affinity chromatography. Gupta RK; Silver HK; Reisfeld RA; Morton DL Cancer Res; 1979 May; 39(5):1683-95. PubMed ID: 427806 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]